Study data

Immune signals and treatment response in PDO 2.0

Separate renal and lung cancer studies show tissue images, immune-related signals and post-treatment cell responses in PDO 2.0.

Request the full white paper View study evidence ↘

Model & sampleccRCC and NSCLC PDO 2.0 study models

Study setupIL-2 and immune-checkpoint study conditions

AssaysccRCC: PanCK, CD3, PD-L1, CD8, CD56 and apoptosis/necrosis flow; NSCLC: CD4/CD8 counts within CD3-positive TILs.

STUDY AND RESULTS

Tumor and immune readouts

Tissue baseline, immune stimulation and treatment-response readouts offer complementary views for tumor–immune studies.

01Tissue and model context

Compare tumor-epithelial and sample-associated immune signals

PanCK, CD3 and DAPI imaging compare tumor-epithelial and immune signals in source tissue and PDOs at days 7 and 28.

02Stimulation response

Tissue response to IL-2 stimulation

CD3, PanCK and DAPI images compare immune and epithelial signals with and without IL-2.

03Treatment response

Immune and cell-death changes after ICB

Control and ICB conditions compare PD-L1, CD8 and CD56 profiles with early-apoptosis and necrosis readouts.

View the complete study figure set

ccRCC tissue and PDO culture characterization, IL-2 stimulation and ICB-related flow readouts in PDO 2.0 — The complete figure set for tissue and culture context, IL-2 stimulation and ICB-related flow readouts.

Study design and assay options

IMAGING & FLOW ASSAYS

Choose models and assays for immunotherapy studies

Study stageMeasured endpointsHow results inform your programStudy extensions

01Source tissue + PDO d7/d28

PanCK, CD3, DAPI and tissue morphology

Measurable tumor context and immune signals

Multi-field quantification, replication and sample-specific windows

02±IL-2 conditions

CD3, PanCK and DAPI immunofluorescence

Interpretable change after immune stimulation

Dose/time, cytokine and gating analyses

03Control + ICB conditions

PD-L1-, CD8- and CD56-associated flow profiles with apoptosis and necrosis

Relationship between immune change and cell-death readouts

Candidate mechanism, target context and independent-sample comparisons

Study application

The ccRCC tissue and ICB-response study and TIL counts from a separate NSCLC project provide complementary immune information for selecting imaging, flow and functional endpoints around the candidate mechanism.

EXTEND THE STUDY

Build the study around the candidate mechanism

Immuno-oncology studies

Combine baseline immune profiling, treatment conditions and cell-death readouts in one study.

↗

Antibody, multispecific and TCE

Select the model and assays around target, effector cells and killing endpoints.

↗

Mechanism and biomarkers

Add mechanistic endpoints and confirmatory studies for priority response signals.

↗

Related models and services

Explore related models and services

DOCUMENT REQUEST

Request the full white paper on PDO 2.0 / ALI

Share your name, organization and work contact details, with your research area if useful. After reviewing the request, our team will contact you to confirm the delivery method and arrange the full white paper.

Request the full white paper See how we work ↗